Company presentations are the cornerstone of the annual J.P. Morgan Healthcare Conference, but one of the most well-attended talks at this year's meeting was delivered by Kimberly Powell, vice president and general manager of health care at NVIDIA. Given that what happens at JPM is a reliable indicator of things to come, this year is set to be the year big tech takes a prominent seat at the biopharma table.
Big Tech's Growing Biopharma Prominence
If activity at the recent J.P. Morgan Healthcare Conference is an indication of what is up ahead, 2024 is set to be the year of big tech in biopharma.
More from Market Intelligence
More from In Vivo
• By
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
• By
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.